Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: Connect Tissue Res. 2017 May 19;59(2):129–146. doi: 10.1080/03008207.2017.1313248

Figure 5: Inhibition of MAPK activity may inhibit ASC osteogenesis.

Figure 5:

Panel A - Expression of the osteogenic genes Runx-2, AP, OP, and OC after ASC osteo-induction was quantified after 21 days and expressed relative to non-induced controls (Gene Expression, -fold change vs. CM) to confirm ASC osteogenic capacity. Panel B - The effect of continuous administration of the indicated MAPK inhibitors on the expression of these osteogenic genes is shown relative to untreated OM controls containing inhibitor vehicle (-fold change vs. OM/vehicle). Panel C – Decreased mineralization versus controls was measured in osteo-induced ASCs treated either continuously for 21 or 35 days with the indicated MAPK inhibitors (ASC Mineralization Capacity, -fold change vs. OM/vehicle). The kinase affected by each inhibitor is given in parentheses. SP600125 was administered during the first seven days of induction to minimize cell death. * indicates a significance difference (p<0.05; t-test) between groups. MAPK inhibitors not significantly affecting mineralization versus controls are not shown.